The capsid protein (CA) of HIV-1 plays essential roles in multiple steps of the viral replication cycle by assembling into functional capsid core, controlling the kinetics of uncoating and nuclear entry, and interacting with various host factors. Targeting CA represents an attractive yet underexplored antiviral approach. Of all known CA-targeting small molecule chemotypes, the peptidomimetic PF74 is particularly interesting because it binds to the same pocket used by a few important host factors, resulting in highly desirable antiviral phenotypes. However, further development of PF74 entails understanding its pharmacophore and mitigating its poor metabolic stability. We report herein the design, synthesis, and evaluation of a large number of PF74 analogs aiming to provide a comprehensive chemical profiling of PF74 and advance the understanding on its detailed binding mechanism and pharmacophore. The analogs, containing structural variations mainly in the aniline domain and/or the indole domain, were assayed for their effect on stability of CA hexamers, antiviral activity, and cytotoxicity. Selected analogs were also tested for metabolic stability in liver microsomes, alone or in the presence of a CYP3A inhibitor. Collectively, our studies identified important pharmacophore elements and revealed additional binding features of PF74, which could aid in future design of improved ligands to better probe the molecular basis of CA-host factor interactions, design strategies to disrupt them, and ultimately identify viable CA-targeting antiviral leads.
|Original language||English (US)|
|Journal||European Journal of Medicinal Chemistry|
|State||Published - Aug 15 2020|
Bibliographical noteFunding Information:
This research was supported by the National Institutes of Health (R01AI120860 to SGS and ZW). We thank the Minnesota Supercomputing Institute for molecular modeling resources.
This research was supported by the National Institutes of Health ( R01AI120860 to SGS and ZW). We thank the Minnesota Supercomputing Institute for molecular modeling resources.
© 2020 Elsevier Masson SAS
Copyright 2020 Elsevier B.V., All rights reserved.
- Capsid-targeting antivirals